Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.49 |
| ▸ | TAS1R2 | Q8TE23 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22813952 | 0.94 | TRPV1 (0.47) | TAS1R3TAS1R1TAS1R2LMNATRPV1 | |
| SCHEMBL12669383 | 0.94 | TRPV1 (0.47) | TAS1R3TAS1R1TAS1R2LMNATRPV1 | |
| SCHEMBL28677537 | 0.89 | TAS1R3 (0.55) | TAS1R3TAS1R1TAS1R2DRD4 | |
| SCHEMBL22501388 | 0.89 | TAS1R3 (0.55) | TAS1R3TAS1R1TAS1R2DRD4 | |
| SCHEMBL24619645 | 0.88 | TAS1R3 (0.51) | TAS1R3TAS1R1TAS1R2LMNADRD4 | |
| SCHEMBL13974252 | 0.88 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2LMNADRD4 | |
| SCHEMBL13974108 | 0.88 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2LMNADRD4 | |
| SCHEMBL17018837 | 0.88 | TRPV1 (0.45) | TAS1R3TAS1R1TAS1R2LMNATRPV1 | |
| SCHEMBL29771900 | 0.88 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2LMNADRD4 | |
| SCHEMBL22501499 | 0.86 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | TAS1R3 1103/4885TAS1R1 945/4885TAS1R2 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.